Company / Cash & Equivalents
BeOne Medicines Ltd. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$4.5B
FY2025
5-year range
$2.6B / $4.5B
FY2021-FY2025
Trend
+73.1%
vs FY2024
Sector context
#8 of 207
Health Care
What the data says
Among 207 Health Care companies, BeOne Medicines Ltd. is in the top 4% for cash & equivalents. Cash & Equivalents returned to growth in FY2025 after 3 years of decline, reaching $4.5B.
Based on SEC 10-K filings.
$4.5B in FY2025 with a 5-year CAGR of +26.9%. Top quartile in the Health Care sector.
Improved from $3.2B to $4.5B over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +5.5%
- 5-Year CAGR
- +26.9%
- 10-Year CAGR
- -
Sector benchmark
Top 4% in Health CareTop 4% of 207This company $4.5B Sector average $669.5M
▼
+579.3% above sector average
Key checks
Key Insights
- 5-year CAGR of +26.9%, indicating consistent growth.
- In FY2025, cash & equivalents increased 73.1% year-over-year.
- Ranks #8 out of 207 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.82 (distress zone, below 1.8 threshold)
- Negative profit margin: -16.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.5B | +73.1% |
| FY2024 | $2.6B | -17.2% |
| FY2023 | $3.2B | -18.0% |
| FY2022 | $3.9B | -11.6% |
| FY2021 | $4.4B | +216.6% |
| FY2020 | $1.4B | +123.6% |
| FY2019 | $618.0M | -13.3% |
| FY2018 | $712.9M | +197.6% |
| FY2017 | $239.6M | +173.8% |
| FY2016 | $87.5M | +389.8% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026